Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders

The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of...

Full description

Saved in:
Bibliographic Details
Main Authors Di Padova, Franco, Huber, Thomas, Rondeau, Jean-Michel Rene
Format Patent
LanguageEnglish
Published 27.11.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL-17A and IL-17AF), are capable of inhibiting IL- 17A induced cytokine production in in vitro assays, having an inhibitory effect in an antigen-induced arthritis model in vivo, and can selectively bind to homodimeric IL-17A and heterodimeric IL-17AF across several species. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
Bibliography:Application Number: NZ20140709739